---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113828"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:44:21.086620+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q3 net loss $34.1M; earns $50M milestone from Janssen for JNJ-2113 Phase 3

## Summary
- Net loss of $34.1M ($0.58 per share) vs $31.2M loss in Q3 2022; R&D expenses rose to $30.7M.
- Cash, equivalents and marketable securities $322.7M as of Sep 30, 2023; cash runway through Q1 2026.
- JNJ-2113 Phase 3 ICONIC-LEAD, ICONIC-TOTAL trials and Phase 2b ANTHEM-UC trial initiated in Q4 2023.
- Dosing of third patient in ICONIC-LEAD triggered $50M milestone from Janssen in October 2023.
- Five rusfertide abstracts accepted for oral/poster presentations at ASH 2023 annual meeting.

## SEC filing metadata
- accession: 0001104659-23-113828
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/0001104659-23-113828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/tm2329667d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113828
- JSON: https://secwatch.observer/filing/0001104659-23-113828.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113828.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Protagonist Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465923113828/0001104659-23-113828-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.